FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Investor's Business Daily on MSN21h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
The company, a spinoff from German group Eckert & Ziegler, achieved a market capitalization of 126.5 million euros ($139.7 million) at its listing price of 5.10 euros. However, shares fell below that ...
Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...
IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb ...
The latest health news highlights include Kailera Therapeutics' $400 million funding, potential CVS Health restructuring, ...
Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback